OrthoPediatrics acquires Boston Orthotics & Prosthetics for $22M cash plus stock; secures $80M debt financing

ORTHOPEDIATRICS CORP

Acquired Boston O&P for $22M upfront cash plus ~83,000 restricted shares (~$2.5M) to employees.
Boston O&P has ~$25M annual revenue, 26 patient care clinics, and partnerships with major children's hospitals.
Acquisition expands OrthoPediatrics' Specialty Bracing division into $500M U.S. pediatric orthotic bracing market.
Closed $80M credit facility with MidCap Financial (term loan $30M, revolver $50M), replacing prior $50M line.
Combined entities have helped over 1 million children; targeting all 300 high-volume children's hospitals.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ORTHOPEDIATRICS CORP entered into Stock Purchase Agreement with Boston Brace International, Inc., the shareholders of Boston Brace (collectively, the Sellers) valued at $22 million in cash (effective 2024-01-05).

Action: entry
Agreement: asset purchase
Counterparty: Boston Brace International, Inc., the shareholders of Boston Brace (collectively, the Sellers)
Value: $22 million in cash
Effective: 2024-01-05

Exact text from the filing

On January 5, 2024, OrthoPediatrics Corp. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Boston Brace International, Inc., a Massachusetts corporation (“Boston Brace”), the shareholders of Boston Brace (collectively, the “Sellers”), and the Sellers’ representative named therein (the “Sellers’ Representative”), pursuant to which the Company acquired all of the issued and outstanding shares of capital stock of Boston Brace from the Sellers.

View on SEC.gov

Browse all material agreements →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001104659-24-002071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.